Company news

Roivant Sciences Ltd. news in 2022

Roivant Sciences Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

November 30, 2022

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

November 13, 2022

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

November 9, 2022

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

November 7, 2022

Roivant Sciences Announces Proposed Public Equity Offering

November 6, 2022

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

October 17, 2022

Roivant to Participate in September Investor Events

August 29, 2022

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

August 14, 2022

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

August 2, 2022

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

June 27, 2022

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

June 27, 2022

Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

June 14, 2022

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

May 23, 2022

Roivant to Present at Upcoming Investor Conferences

May 18, 2022

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

May 15, 2022

Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation

May 1, 2022

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

March 24, 2022

Roivant to Present at Targeted Protein Degradation Conference

March 10, 2022

Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update

February 13, 2022

Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022

February 6, 2022

Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Calls in 2022

Decks in 2022